BR112019003622A2 - método para produção de uma proteína de fusão. - Google Patents
método para produção de uma proteína de fusão.Info
- Publication number
- BR112019003622A2 BR112019003622A2 BR112019003622-9A BR112019003622A BR112019003622A2 BR 112019003622 A2 BR112019003622 A2 BR 112019003622A2 BR 112019003622 A BR112019003622 A BR 112019003622A BR 112019003622 A2 BR112019003622 A2 BR 112019003622A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- producing
- column chromatography
- mammalian cells
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-164901 | 2016-08-25 | ||
| JP2016164901 | 2016-08-25 | ||
| PCT/JP2017/030470 WO2018038243A1 (ja) | 2016-08-25 | 2017-08-25 | 抗体融合蛋白質の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003622A2 true BR112019003622A2 (pt) | 2019-05-21 |
Family
ID=61246169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003622-9A BR112019003622A2 (pt) | 2016-08-25 | 2017-08-25 | método para produção de uma proteína de fusão. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11512135B2 (https=) |
| EP (1) | EP3505538B1 (https=) |
| JP (2) | JP6993814B2 (https=) |
| KR (1) | KR102318480B1 (https=) |
| CN (1) | CN109641971B (https=) |
| AU (1) | AU2017316955B2 (https=) |
| BR (1) | BR112019003622A2 (https=) |
| CA (1) | CA3034589A1 (https=) |
| MX (1) | MX389073B (https=) |
| SG (1) | SG11201901495YA (https=) |
| WO (1) | WO2018038243A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| AU2016283344B2 (en) | 2015-06-24 | 2022-08-04 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein containing BDNF |
| KR102497564B1 (ko) | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
| CA3052936A1 (en) | 2016-12-26 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of bdnf and anti-transferrin receptor antibody |
| CN111278453A (zh) * | 2017-09-07 | 2020-06-12 | Jcr制药股份有限公司 | 水性药物组合物 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| IL276327B2 (en) * | 2018-02-05 | 2024-05-01 | Japan Chem Res | Method for delivering drug to muscle |
| EP3560945A1 (en) * | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
| JP6951051B2 (ja) * | 2018-05-24 | 2021-10-20 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| KR102692543B1 (ko) * | 2018-10-26 | 2024-08-07 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| TW202342542A (zh) * | 2020-12-23 | 2023-11-01 | 大陸商廣東菲鵬製藥股份有限公司 | 抗pd-l1抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物及其用途 |
| EP4291246A4 (en) * | 2021-02-11 | 2024-12-11 | Denali Therapeutics Inc. | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF |
| EP4299756A4 (en) | 2021-03-09 | 2025-03-12 | JCR Pharmaceuticals Co., Ltd. | METHOD FOR PRODUCING AN ANTIBODY LYSOSOMALIC ENZYMFUSION PROTEIN |
| CA3244685A1 (en) * | 2021-12-28 | 2025-06-13 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of anti-transferrin receptor antibody and physiologically active protein for safe gene therapy |
| WO2024010067A1 (ja) * | 2022-07-08 | 2024-01-11 | Ｊｃｒファーマ株式会社 | 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤 |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537273A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| MY157915A (en) * | 2004-12-21 | 2016-08-15 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses. |
| EP2089424B1 (en) | 2006-12-06 | 2015-07-01 | JCR PHARMACEUTICALS Co., LTD. | Method for production of human erythropoietin |
| MX2009006398A (es) * | 2006-12-12 | 2009-06-23 | Biorexis Pharmaceutical Corp | Genotecas de proteinas de fusion de transferrina. |
| JP2009273427A (ja) | 2008-05-16 | 2009-11-26 | Jcr Pharmaceuticals Co Ltd | 組換え体ヒトｆｓｈの製造方法 |
| US8058407B2 (en) * | 2008-10-31 | 2011-11-15 | Wyeth Llc | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| JP6018572B2 (ja) * | 2011-01-25 | 2016-11-02 | Ｊｃｒファーマ株式会社 | 組換えヒトイズロン酸−２−スルファターゼの製造方法 |
| BR112014013250A2 (pt) * | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima alvo e usos dos mesmos |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| WO2014016873A1 (en) * | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
| EP3088518A4 (en) | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| JP6071018B2 (ja) | 2014-10-31 | 2017-02-01 | Ｊｃｒファーマ株式会社 | 組換えヒトＤＮａｓｅＩの製造方法 |
| WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
-
2017
- 2017-08-25 SG SG11201901495YA patent/SG11201901495YA/en unknown
- 2017-08-25 JP JP2017161826A patent/JP6993814B2/ja active Active
- 2017-08-25 WO PCT/JP2017/030470 patent/WO2018038243A1/ja not_active Ceased
- 2017-08-25 CA CA3034589A patent/CA3034589A1/en active Pending
- 2017-08-25 BR BR112019003622-9A patent/BR112019003622A2/pt unknown
- 2017-08-25 CN CN201780051299.5A patent/CN109641971B/zh active Active
- 2017-08-25 US US16/327,982 patent/US11512135B2/en active Active
- 2017-08-25 MX MX2019002252A patent/MX389073B/es unknown
- 2017-08-25 EP EP17843719.0A patent/EP3505538B1/en active Active
- 2017-08-25 AU AU2017316955A patent/AU2017316955B2/en active Active
- 2017-08-25 KR KR1020197007992A patent/KR102318480B1/ko active Active
-
2021
- 2021-12-10 JP JP2021200504A patent/JP7232889B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11512135B2 (en) | 2022-11-29 |
| KR20190040040A (ko) | 2019-04-16 |
| JP2022028959A (ja) | 2022-02-16 |
| JP6993814B2 (ja) | 2022-01-14 |
| CN109641971A (zh) | 2019-04-16 |
| MX389073B (es) | 2025-03-20 |
| WO2018038243A1 (ja) | 2018-03-01 |
| SG11201901495YA (en) | 2019-03-28 |
| CN109641971B (zh) | 2023-04-04 |
| KR102318480B1 (ko) | 2021-10-28 |
| CA3034589A1 (en) | 2018-03-01 |
| JP7232889B2 (ja) | 2023-03-03 |
| US20190225700A1 (en) | 2019-07-25 |
| JP2018033454A (ja) | 2018-03-08 |
| EP3505538A1 (en) | 2019-07-03 |
| AU2017316955A1 (en) | 2019-03-21 |
| MX2019002252A (es) | 2019-07-04 |
| AU2017316955B2 (en) | 2022-03-03 |
| EP3505538B1 (en) | 2024-05-01 |
| EP3505538A4 (en) | 2020-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003622A2 (pt) | método para produção de uma proteína de fusão. | |
| Paul et al. | Biogenesis of cytosolic and nuclear iron–sulfur proteins and their role in genome stability | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| MX2019002498A (es) | Metodos y productos para la expresion de proteinas en celulas. | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| HK1218297A1 (zh) | 用於生产单克隆抗体的改进方法 | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| CU23791A3 (es) | Método para la producción de proteínas y anticuerpos mejorados | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
| MX2021000210A (es) | Metodos y productos para transfeccion de celulas. | |
| BR112017003236A2 (pt) | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| NZ630568A (en) | Methods and means for the production of ch3 domain-comprising molecules | |
| BR112015009774A2 (pt) | polipeptídeos citocromo p450 e citocromo p450 redutase, codificando moléculas de ácido nucléicos e usos das mesmas | |
| PE20190229A1 (es) | Anticuerpos anti-fcrn | |
| BR112023018268A2 (pt) | Método para produzir uma proteína de fusão | |
| BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
| BR112018068303A2 (pt) | método de cultivo e/ou monitoramento de células epiteliais usando um sistema de cultura celular microfluida, uso das células no sistema de cultura celular microfluida, composição ou sistema e sistema de cultura celular microfluida | |
| BR112016012229A2 (pt) | métodos de produção de polipeptídeos | |
| HK1209790A1 (en) | Method of producing recombinant iduronate-2-sulfatase | |
| BR112015005081A8 (pt) | Método para produzir um polissacarídeo capsular tendo um sorotipo de pneumococo | |
| BR112016023823A2 (pt) | método para produção de um produto de fermentação | |
| BR112016013371A2 (pt) | melhorias em proteína de fusão pesticida | |
| WO2012096552A3 (ko) | Ｒｅｘ１을 포함하는 세포 리프로그래밍 조성물 및 이를 이용한 유도 만능줄기세포 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |